Alphatec (NASDAQ:ATEC) Trading Down 10.4% - Time to Sell?

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report)'s share price dropped 10.4% during trading on Tuesday . The company traded as low as $10.13 and last traded at $11.00. Approximately 556,575 shares changed hands during trading, a decline of 71% from the average daily volume of 1,910,448 shares. The stock had previously closed at $12.27.

Wall Street Analysts Forecast Growth

ATEC has been the topic of a number of analyst reports. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler raised their target price on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Finally, Barclays raised their target price on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $17.67.

Remove Ads

Alphatec Price Performance

The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The stock has a 50 day moving average price of $10.91 and a two-hundred day moving average price of $8.60. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -8.17 and a beta of 1.39.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. As a group, analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling

In related news, EVP David Sponsel sold 58,283 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares of the company's stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Patrick Miles sold 50,000 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the transaction, the chief executive officer now directly owns 6,152,544 shares of the company's stock, valued at $74,015,104.32. The trade was a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 303,589 shares of company stock valued at $3,462,743 in the last three months. 22.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning lifted its holdings in Alphatec by 83.9% during the 3rd quarter. Creative Planning now owns 48,611 shares of the medical technology company's stock worth $270,000 after buying an additional 22,171 shares during the last quarter. Stephens Inc. AR lifted its holdings in Alphatec by 51.4% during the 3rd quarter. Stephens Inc. AR now owns 21,743 shares of the medical technology company's stock worth $121,000 after buying an additional 7,382 shares during the last quarter. Van ECK Associates Corp lifted its holdings in Alphatec by 57.0% during the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company's stock worth $99,000 after buying an additional 6,998 shares during the last quarter. Atria Investments Inc lifted its holdings in Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company's stock worth $109,000 after buying an additional 1,460 shares during the last quarter. Finally, Entropy Technologies LP lifted its holdings in Alphatec by 14.9% during the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company's stock worth $120,000 after buying an additional 2,800 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.